AI Cytology and Digital Pathology
Solutions
Founded in 2000, Landing Med is a medtech company focused on early cancer detection solutions. We offer affordable and accessible AI-powered cytology & digital pathology technologies to empower laboratories worldwide to enhance diagnostic precision, efficiency, and confidence. As a globally recognized leader in cervical cytology screening, we have successfully screened over 10 million women and strive to make pathology accessible to all.
Read More
____________
Our Products
____________
Global Publications
____________
Testimonials
____________
In the Press
____________
Landing Med Certifications
____________
Our Partners
Portable Digital Pathology
Slide Scanner
LD Patho 320
High Throughput Digital Pathology Slide Scanner
LD Cyto2200
AI Cervical Cytology System
2023, The Lancet Regional
Health-Western Pacific
Cost-effectiveness of artificial intelligenceassisted liquid-based cytology testingfor
cervical cancer screening in China
Read More
2021, Cervical Cancer
Role of Al in Cervical Cancer Screening
The artificial intelligence-assisted cytology
diagnostic system in large-scale cervical cancer
screening: A population-based cohort study of
0.7 million women
2020, Cancer Medicine
Chinese Medtech Company Landing Med Surpasses 10 Million AI-Assisted Pap Smear Screenings
Smart screening broadens cervical cancer monitoring
Foreword: Accelerating Cervical Cancer Prevention and Control in China to Achieve .....
Landing Med Recognized by Forbes China as a "2024 Top Innovative Healthcare Company"
Let's get in touch
|
|